

LETTER TO THE EDITOR

Open Access



Neurofibrillary tangle-predominant dementia followed by amyloid β pathology: a clinico-radio-pathological case providing insights into current disease-modifying therapeutic strategy

Tomoyasu Matsubara¹, Kenji Ishii², Yoko Saito³, Aya Midori Tokumaru⁴, Akira Arakawa¹, Manato Hara¹, Masanori Kurihara³, Renpei Sengoku^{1,5}, Kazutomi Kanemaru³, Atsushi Iwata³, Tomio Arai⁶, Akinori Miyashita⁷, Takeshi Ikeuchi⁷, Masato Hasegawa⁸, Shigeo Murayama^{1,3,9} and Yuko Saito^{1*}

Neurofibrillary tangle (NFT)-predominant dementia/primary age-related tauopathy (NFTD/PART) is an entity presenting with the deposition of NFT mainly in the medial temporal lobe. It is distinct from Alzheimer's disease (AD) in that it shows minimal deposition of amyloid

β (A β) plaques [3, 6, 10]. Recently, based on the amyloid cascade hypothesis, A β -targeting disease-modifying therapies (DMTs) for AD have been developed [9]. The dilemma, however, is that A β deposition is observed frequently in the advanced ages regardless of the presence of AD [8]. Thus, A β plaque accumulation can occur concurrently in patients presenting with other dementing conditions. This situation complicates the efficacy of DMTs, making accurate differentiation between conditions crucial for effective treatment, especially considering the high costs and potential side effects of DMTs. Here, we report a clinico-radio-pathologically-confirmed case that initially developed NFTD/PART and then gradually developed overlapping A β pathology, highlighting its importance in the context of DMTs.

An 88-year-old man without a significant past medical history or family history of neurological disorders presented with mild cognitive decline (Mini-Mental State Examination [MMSE] score: 26/30). Bilateral atrophy and reduced radioligand uptake in the medial temporal lobes were observed on MRI and [¹⁸F]-2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET), respectively (Fig. 1). At age 90, cerebrospinal fluid A β , phosphorylated tau, and tau levels were normal. [¹¹C]-Pittsburgh compound-B (PiB) PET,

*Correspondence:

Yuko Saito
yukosm@bbarjp.net

¹ Department of Neuropathology (the Brain Bank for Aging Research [BBAR]), Tokyo Metropolitan Institute for Geriatrics and Gerontology, 35-2 Sakae-cho, Itabashi-ku, Tokyo 173-0015, Japan

² Research Team for Neuroimaging, Tokyo Metropolitan Institute for Geriatrics and Gerontology, Tokyo, Japan

³ Department of Neurology, Tokyo Metropolitan Institute for Geriatrics and Gerontology, Tokyo, Japan

⁴ Department of Diagnostic Radiology, Tokyo Metropolitan Institute for Geriatrics and Gerontology, Tokyo, Japan

⁵ Department of Neurology, The Jikei University Daisan Hospital, Tokyo, Japan

⁶ Department of Pathology, Tokyo Metropolitan Institute for Geriatrics and Gerontology, Tokyo, Japan

⁷ Department of Molecular Genetics, Brain Research Institute, Niigata University, Niigata, Japan

⁸ Department of Brain and Neurosciences, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan

⁹ Brain Bank for Neurodevelopmental, Neurological and Psychiatric Disorders, United Graduate School of Child Development, Osaka University, Osaka, Japan



© The Author(s) 2024. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.




Fig. 1 Chronological clinical and positron emission tomography (PET) findings (a). Presenting with mild cognitive impairment, bilaterally reduced radioligand uptake in the medial temporal lobes was observed on [18F]-2-fluoro-2-deoxy-D-glucose (FDG)-PET. However, cerebrospinal fluid (CSF) amyloid β (A β), phosphorylated tau, and tau levels were normal, and [11C]-Pittsburgh compound-B (PiB) PET also indicated no significant A β deposition. After that, with the progression of cognitive dysfunction, there was a gradual increase in A β accumulation in the cerebrum. Centiloid scaling was used to standardize the results of amyloid PET quantitatively. Centiloid scale values range from 0 to 100, with 0 representing definitively A β -negative brains of young, healthy controls and 100 representing the average signal observed in patients with mild to moderate dementia due to Alzheimer's disease. Centiloid scale transition also supports the fact that A β accumulation began after the onset of dementia and showed a slow increase. Color bars indicate the standardized uptake value ratio (SUVR). Comparison of T1-weighted MRI images at ages 88 and 97 (b). The overall brain atrophy progressed only modestly despite the 9-year follow-up interval under the dementing condition, while the hippocampal atrophy became more pronounced, extending to the posterior regions. Abbreviations: MMSE Mini-Mental State Examination score, y.o. years old

detecting both diffuse and cored A β plaques [5], also showed no significant A β deposition. At age 91, he presented with topographical disorientation and showed a lower MMSE score (total 20/30; word recall 0/3). Based on these findings, the patient received a diagnosis of non-A β -related dementia, such as argyrophilic grain dementia or NFTD/PART. Subsequently, a cognitive impairment progressed slowly. Subsequent PiB PET at age 92 revealed focal A β deposition in the parietal and temporal lobes and at age 97 A β deposition throughout the cerebrum (Fig. 1a). In contrast, the overall brain atrophy progressed only mildly despite the 9-year follow-up interval under the dementing condition, while the hippocampal atrophy became more pronounced, extending to the posterior regions (Fig. 1b). The patient died of aspiration pneumonia at age 97.

Autopsy was performed 5 h after death. The brain weighed 1,137 g before fixation. A detailed description of the neuropathological examination methods is provided in Supplementary Information. Macroscopic examination revealed bilateral hippocampal atrophy (Fig. 2a). Microscopic examination revealed severe neuronal loss (Fig. 2b) and gliosis in the hippocampal CA1 region with

abundant NFTs (Fig. 2c, d), predominantly extracellular ghost tangles (Fig. 2e, f). Many NFTs were observed in the hippocampus, including the dentate gyrus. NFTs were confined to the temporal lobe (Fig. 2g), while there was minimal distribution in other neocortices (Braak NFT stage IV). These NFTs were immunoreactive for both 4-repeat and 3-repeat tau. A β plaques were present throughout the cortex and striatum; however, their amount was up to moderate, and the plaques were mainly diffuse plaques as well as cored plaques (corresponding to Thal phase: 3, CERAD score: moderate) (Fig. 2h). Other aging/dementia-related pathologies were as follows: BBAR Lewy stage II (prodromal stage), Saito argyrophilic grain stage I, no TDP-43 pathology was identified. The vascular pathology was also minimal.

In addition, immunoblotting of the temporal cortex tissue revealed phosphorylated triplet tau bands (60, 64, and 68 kDa), consistent with NFTD/PART or AD. The patient's APOE genotype was ϵ 3/3. No MAPT pathological mutation was detected.

Clinico-radiologically, the patient exhibited cognitive decline preceding sufficient A β deposition, and, during the disease course, A β deposition became progressively




Fig. 2 Neuropathological findings. Macroscopic examination showed selective hippocampal atrophy (a). Klüver–Barrera staining revealed severe neuronal loss in the hippocampal CA1 region (b). Gallyas staining revealed severe neurofibrillary tangles (NFTs), predominantly extracellular ghost tangles (c, d). Methenamine silver staining showed few plaques but abundant extracellular ghost tangles (e, f [magnified image of square in panel e]). Phosphorylated tau immunostaining showed NFTs distributed in the temporal lobe (g). Amyloid β immunostaining shows a mixture of diffuse and cored plaques in amounts up to moderate (h; taken in the middle temporal gyrus). Immunoblot analysis of sarkosyl-insoluble tau. Western blotting with an anti-tau antibody (clone T46, mouse monoclonal, dilution 1:1000, Thermo Fisher Scientific, Rockford, USA) detected full-length hyperphosphorylated tau bands with apparent molecular weight of 60, 64, and 68 kDa, consistent with NFT-predominant dementia/primary age-related tauopathy or Alzheimer’s disease tau banding pattern (i). Scale bars: 1 cm (a), 1 mm (b, c, and e), 50 μ m (d), 20 μ m (f), 5 mm (g), and 100 μ m (h)

evident. Neuropathological analysis displayed a characteristic finding of NFTs densely filling the hippocampus, consistent with advanced NFTD/PART [10]. The amount of A β plaques was also relatively small, and diffuse plaques predominated, which is not typical for AD. Although the brain condition at autopsy was categorized as intermediate AD according to the National Institute on Aging–Alzheimer’s Association criteria [7] and did not meet the NFTD/PART criteria [3, 10], the longitudinal PET findings suggest that the pathological findings would have met the criteria for NFTD/PART if the brain was examined at a little earlier stage in his life. Namely, the longitudinal clinicoradiological observations combined with the autopsy results indicate that NFTD/PART pathology was initially developed, followed by a subsequent overlap with A β pathology. In fact, this patient’s slower progression of cognitive decline, which deviated from the expected annual MMSE score decrement associated with AD (approximately 3 points/year) [2, 4], is consistent with the characteristics of NFTD/PART [1]. Furthermore, the mean age at onset of NFTD/PART has been documented as 89 years [range 81–95 years] [11]. Indeed, this patient also developed dementia at around 90 years of age. Therefore, NFTD/PART should be considered in the differential diagnosis of patients with the features described above; in addition, it should be noted that NFTD/PART may sometimes be comorbid with mild A β pathology with aging.

Recognizing the existence of such overlapping pathological conditions is becoming increasingly important with the advent of A β -targeting DMTs for AD. In such cases where sufficient tau accumulation for the dementing condition development precedes sufficient A β deposition, “tau-first condition”, tau accumulation and neuronal loss may be substantially advanced relative to A β levels. This condition may lead to a misidentification of the appropriate treatment subjects, potentially reducing the efficacy of A β -targeting DMTs in delaying the dementia progression compared with the AD cases obediently following the amyloid cascade hypothesis, “amyloid-first condition”. Thus, the existence of such overlapping conditions underscores the need to deeply understand the heterogeneity of the current DMT candidates and optimize the DMT eligibles.

In conclusion, this NFTD/PART case with overlapping A β pathology illustrates the complexity of diagnosing and treating neurodegenerative diseases, particularly in an aging population. This highlights the need for a more comprehensive understanding of the pathological basis of dementia syndromes which extends beyond the simplistic A β -centric model of AD.

Abbreviations

AD	Alzheimer’s disease
A β	Amyloid β
BBAR	The Brain Bank for Aging Research
DMT	Disease-modifying therapy
FDG	[¹⁸ F]-2-fluoro-2-deoxy-D-glucose
MMSE	Mini-Mental State Examination

NFT	Neurofibrillary tangle
NFTD/PART	NFT-predominant dementia/primary age-related tauopathy
PET	Positron emission tomography
PiB	[¹¹ C]-Pittsburgh compound-B

Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s40478-024-01815-x>.

Supplementary Material 1.

Acknowledgements

The authors would like to thank Ms. Mieko Harada, Mr. Yutaka Koga, Ms. Natsumi Kawada, and Ms. Manami Itagaki for their technical assistance.

Author contributions

TM analyzed and interpreted the data and drafted the manuscript. KI, SM, and YS designed and conceptualized the study, analyzed and interpreted the data, and revised the manuscript. YoS, AMT, RS, and KK collected the clinical data and revised the manuscript. AA, ManH, MK, AI, TA, AM, TI, and MasH analyzed and interpreted the data and revised the manuscript. All authors read and approved the final manuscript.

Funding

This work was supported by AMED under Grant Nos. JP22wm0425019 (S.M., Y.S.), JP20dm0107106 (S.M.), JP20dm0107103 (Y.S.), and JP24dk0207060 (T.I.), and JSPS KAKENHI JP22K15740 (T.M.), JP22H04923 (CoBIA) (S.M., Y.S.), JP22K07538 (S.M.), JP22K07550 (Y.S.), and JP21K07271 (A.M.), and MHLW Research on rare and intractable diseases Program Grant No. JPMH23FC1008 (Y.S.).

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author upon reasonable request.

Declarations

Ethics approval and consent to participate

This investigation was performed in line with the principles of the Declaration of Helsinki. The report was approved by the local institutional ethics committee.

Consent for publication

The patient's family provided written informed consent for the autopsy and publication of this case and any accompanying data.

Competing interests

The authors declare no conflict of interest.

Received: 28 April 2024 Accepted: 4 June 2024

Published online: 17 June 2024

References

- Bell WR, An Y, Kageyama Y, English C, Rudow GL, Pletnikova O et al (2019) Neuropathologic, genetic, and longitudinal cognitive profiles in primary age-related tauopathy (PART) and Alzheimer's disease. *Alzheimers Dement* 15:8–16. <https://doi.org/10.1016/j.jalz.2018.07.215>
- Clark CM, Sheppard L, Fillenbaum GG, Galasko D, Morris JC, Koss E et al (1999) Variability in annual Mini-Mental State Examination score in patients with probable Alzheimer disease: a clinical perspective of data from the Consortium to Establish a Registry for Alzheimer's Disease. *Arch Neurol* 56:857–862. <https://doi.org/10.1001/archneur.56.7.857>
- Crary JF, Trojanowski JQ, Schneider JA, Abisambra JF, Abner EL, Alafuzoff I et al (2014) Primary age-related tauopathy (PART): a common pathology associated with human aging. *Acta Neuropathol* 128:755–766. <https://doi.org/10.1007/s00401-014-1349-0>
- Han L, Cole M, Bellavance F, McCusker J, Primeau F (2000) Tracking cognitive decline in Alzheimer's disease using the mini-mental state examination: a meta-analysis. *Int Psychogeriatr* 12:231–247. <https://doi.org/10.1017/s1041610200006359>
- Ikonomic MD, Buckley CJ, Abrahamson EE, Kofler JK, Mathis CA, Klunk WE et al (2020) Post-mortem analyses of PiB and flutemetamol in diffuse and cored amyloid- β plaques in Alzheimer's disease. *Acta Neuropathol* 140:463–476. <https://doi.org/10.1007/s00401-020-02175-1>
- Jellinger KA, Attems J (2007) Neurofibrillary tangle-predominant dementia: comparison with classical Alzheimer disease. *Acta Neuropathol* 113:107–117. <https://doi.org/10.1007/s00401-006-0156-7>
- Montine TJ, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Dickson DW et al (2012) National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach. *Acta Neuropathol* 123:1–11. <https://doi.org/10.1007/s00401-011-0910-3>
- Ossenkopppele R, Jansen WJ, Rabinovici GD, Knol DL, van der Flier WM, van Berckel BN et al (2015) Prevalence of amyloid PET positivity in dementia syndromes: a meta-analysis. *JAMA* 313:1939–1949. <https://doi.org/10.1001/jama.2015.4669>
- van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M et al (2023) Lecanemab in early Alzheimer's disease. *N Engl J Med* 388:9–21. <https://doi.org/10.1056/NEJMoa2212948>
- Yamada M (2003) Senile dementia of the neurofibrillary tangle type (tangle-only dementia): neuropathological criteria and clinical guidelines for diagnosis. *Neuropathology* 23:311–317. <https://doi.org/10.1046/j.1440-1789.2003.00522.x>
- Yamada M, Itoh Y, Otomo E, Suematsu N, Matsushita M (1996) Dementia of the Alzheimer type and related dementias in the aged: DAT subgroups and senile dementia of the neurofibrillary tangle type. *Neuropathology* 16:89–98. <https://doi.org/10.1111/j.1440-1789.1996.tb00162.x>

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.